Replies to post #691 on Bristol Myers Squibb (BMY)

[DewDiligence]

Oncology can't be anywhere near 50% of PFE's portfolio. Maybe you were referring to the % of sales in PFE's "GIP" division from products launched during the past few years (e.g. Ibrance).